Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 65829

Title: Liver dysfunction and SARS-CoV-2 infection

Reviewer's code: 00032020
Position: Editorial Board
Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: United States

Manuscript submission date: 2021-03-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-18 09:13

Reviewer performed review: 2021-03-23 08:57

Review time: 4 Days and 23 Hours

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Manuscript NO: 65829 Title: Liver dysfunction and SARS-CoV-2 infection Manuscript Type: Frontier Correspondence to: Abraham Edgar Gracia-Ramos, MD, MSc. This is a comprehensive review about COVID-19. Minor: There were several case reports about portal thrombosis in COVID-19. If possible, authors had better introduce this pathogenesis.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 65829

Title: Liver dysfunction and SARS-CoV-2 infection

Reviewer's code: 01560784
Position: Editorial Board
Academic degree: MD

Professional title: Chief Doctor, Chief Physician, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-03-16

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-28 14:04

Reviewer performed review: 2021-04-06 08:18

Review time: 8 Days and 18 Hours

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

At present, coronavirus disease 2019 (COVID-2019) caused by 2019 novel coronavirus (2019-nCoV) infection has spread rapidly in over 70 countries around the world and thus become a public health event of international concern. In addition to fever and respiratory symptoms, varying degrees of liver injure is also observed after 2019-nCoV infection. This manuscript reviews the epidemiology, clinical features, pathophysiology, and therapeutic strategies of liver injury associated with COVID-2019 in in both patients with or without the pre-existing liver diseases including metabolic related fatty liver disease, liver cirrhosis, liver transplantation, viral hepatitis, autoimmune liver disease and drug-induced liver damage, facilitating clinicians' access to updated information and patient care, so as to provide a reference for clinical decision-making on the prevention and treatment of COVID-2019. The abstract of the manuscript summarize the work of the full text, and the references cited are the latest and important. The manuscript is well, concisely and coherently organized and presented, in which the style, language and grammar is accurate and appropriate. Thus, We recommend that this manuscript be published in full.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 65829

Title: Liver dysfunction and SARS-CoV-2 infection

Reviewer's code: 05450119
Position: Peer Reviewer
Academic degree: PhD

Professional title: Doctor, Postdoc

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-03-16

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-28 11:14

Reviewer performed review: 2021-04-09 17:19

Review time: 12 Days and 6 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

In this study, the authors summarized the current evidence about COVID-19-associated liver injury, including epidemiology, pathophysiology and managemen, in both patients with or without the pre-existing liver disease. The paper is of some interest because-as the authors correctly state-the incidence of COVID-19-associated liver injury is high. However, I have some concerns that have to be dealt with. 1.SARS-CoV-2 infection and liver dysfunction in patients with no previous liver disease-Epidemiology section (page 6-8) Some indicators such as ALT and AST are not specific indicators of liver dysfunction. Myositis is one of the common complications of COVID-19 (Tsivgoulis G, Palaiodimou L, et al. Neurological manifestations and implications of COVID-19 pandemic. Ther Adv Neurol Disord.2020 Jun 9; T Berth SH, Lloyd TE. Secondary Causes of Myositis. Curr Treat Options Neurol. 2020;22(11):38.), and some studies suggested that elevated aminotransferases in COVID-19 could also originate from myositis rather than liver injury (Bangash MN, et al. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020 Jun;5(6):529-530). Therefore, how to accurately determine whether patients have COVID-19-associated liver injury needs further discussion. 2.Epidemiology section It may be better to list and compare similar study in tables. 3.The “kg/m2” word should be corrected as “kg/m2 (superscript)” (page 12). 4.The “P<0•0001” should be corrected as “P<0.0001” (page 17). 5.The “COVI-19” word should be corrected as “COVID-19” (page 21). 6.I suggest adding these references: One world, one pandemic, many guidelines: management of liver diseases during COVID-19. Gut. 2020 Aug;69(8):1369-1372. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol. 2020 Aug;73(2):441-445.